ASRS Live: 27-Gauge vs 25-gauge vitrectomy for symptomatic vitreous opacities
July 31st 2023Our team spoke with Shawn Kavoussi, MD, at the 2023 ASRS meeting in Seattle, Washington about his research on using infrared video for vitreous opacities and comparing postoperative reduction in vitreous opacity scores using infrared video with the Heidelberg spectralis unit.
Read More
ASRS Live: Apellis providing update on review of safety events with pegcetacoplan injection for GA
July 30th 2023During presentations at the American Society for Retina Specialists 41st Annual Meeting in Seattle, the company noted that there was no indication that drug product or manufacturing issues contributed to rare events of retinal vasculitis.
Read More
ASRS Live: Presentations and topics at ASRS that are key for retina specialists
July 30th 2023Our team spoke with Michael Ip, MD, to get his perspective on the 2023 ASRS meeting in Seattle, Washington and why he thinks these are the most valuable topics to understand and review for retina specialists.
Read More
ASRS Live: Regeneron presents aflibercept 8 mg two-year results from PHOTON trial in DME
July 30th 2023In a presentation at the American Society of Retina Specialists 41st Annual Meeting in Seattle, Diana Do, MD, said the PHOTON study demonstrated the impact aflibercept 8 mg could have in reducing the treatment burden for patients diagnosed with DME.
Read More
ASRS Live: Clearside Biomedical’s suprachoroidal injection platform in spotlight in Seattle
July 30th 2023According to the company, a pair of presentations at the American Society of Retina Specialists annual meeting in Seattle highlight CLS-AX as a promising wet AMD treatment with a new mechanism of action and the potential for longer duration of effect than current therapies.
Read More
ASRS 2023: Outcomes and clinical features predictive of fungal endophthalmitis
July 29th 2023Mark Breazzano, MD, FACS, who is presenting Outcomes and Clinical Features Predictive of Fungal Endophthalmitis at the 2023 ASRS meeting in Seattle, Washington spoke with our team about this research.
Read More
ASRS Live: Results of GATHER 1 and GATHER 2 clinical trials with Carl Danzig, MD
July 29th 2023Carl Danzig, MD, spoke with our team to share the exciting results of the GATHER 1 and GATHER 2 clinical trials for avacincaptad pegol for the treatment of geographic atrophy at the 2023 ASRS annual meeting.
Read More
ASRS Live: Aaron Lee, MD, shares updates on deep learning research
July 29th 2023At the 2023 ASRS meeting in Seattle, Washington, Aaron Lee, MD, spoke with our team about his research and how changes are making new training possible. He shared how research and new techniques are expanding the options for deep learning in ophthalmology.
Read More
Opthea announces Sozinibercept as the nonproprietary drug name for OPT-302
July 26th 2023OPT-302 is the company’s novel recombinant “trap” fusion protein targeting inhibition of vascular endothelial growth factors C and D, two ligand mediators of angiogenesis and vascular leakage involved in retinal vascular diseases.
Read More
Applying massive sequencing to identify mutated genes in hereditary eye diseases
July 24th 2023According to the University of Barcelona, the agreement between DBGen Ocular Genomics and Novartis will allow the accurate diagnostics of the genetic bases of these two pathologies to be conducted by mass sequencing of gene panels designed by the UB spin-off.
Read More